Pulmonary Embolism Diagnosed by Improved Interpretation of Blood Tests

D-dimer is a fibrin degradation product (or FDP), a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. It is so named because it contains two D fragments of the fibrin protein joined by a cross-link. A new way to interpret blood test results in patients who are investigated for blood clots in their lungs, and this new approach applies to D-dimer blood tests, which are used by physicians to rule out the presence of a blood clot.

Scientists working with the Hamilton Health Sciences (Hamilton, ON, Canada) enrolled a total of 2,017 patients aged 18 and older who were evaluated in a study, of which 7% had pulmonary embolism on initial diagnostic testing. The average age of the patients was 52 years, and 66% were female. Of the patients in the study, 1,474 (73%) were enrolled at Hamilton Health Sciences or St. Joseph's Healthcare Hamilton. These patients, and those at other university-based clinical centers in Canada, were tested from December 2015 through May 2018 and assessed 90 days later.

The team reported that of the 1,325 patients identified by an emergency department physician as having a low (1,285 of the patients) or a moderate (40 patients) probability of having a pulmonary embolism and who had negative D-dimer results (that is, less than 1,000 or 500 ng/mL, respectively), none had venous thromboembolism during follow-up.

Clive Kearon, MB, MRCPI, FRCPC, PhD, a professor of medicine, and a senior author of the study, said, “The primary goal of diagnostic testing for pulmonary embolism is to identify which patients should be treated with anticoagulant agents and which should not. When a physician is concerned that pulmonary embolism may be present, chest imaging with CT pulmonary angiography is usually done in half of these patients. We wanted to find a way to reduce the number of CT scans that need to be done. Our analyses show that pulmonary embolism is ruled out by a D-dimer level of less than 1,000 ng/mL in patients with a low probability, and by a D-dimer level of less than 500 ng/mL in patients with a moderate probability. This way of using D-dimer testing and clinical assessment reduced the need for CT scanning by one-third.” The study was published on the November 28, 2019 in the New England Journal of Medicine.

Related Links:
Hamilton Health Sciences